Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance.
Meanwhile, CEO Robert B. Ford thinks the overall optimism around Abbott is because of the company’s promising product pipeline, particularly a new over-the-counter product called Lingo.
Lingo: A potential game-changer
Lingo is an over-the-counter version of Libre, Abbott’s popular continuous glucose monitor.
During an interview with CNBC, CEO Ford highlighted the significant potential of Lingo, seeing a multi-billion-dollar opportunity even with modest penetration and utilization rates.
Building on the success of Libre, which is used by over 6 million people daily, Abbott plans to leverage the same platform for Lingo.
The goal is to target individuals who do not have diabetes but are interested in gaining insights to develop healthier habits.
The health care giant has already received FDA approval for Lingo and expects to launch it within the next few weeks.
Financial performance and projections
Despite the recent dip, Abbott stock remains down approximately 15% from its year-to-date high in early March.
However, CEO Ford emphasized the company’s strong financial health and future prospects.
He reiterated Abbott’s commitment to improving its cost profile, aiming to enhance its gross margin by 75 basis points this year.
This potential improvement, combined with a robust product pipeline and strength across all business units, prompted Abbott to raise its full-year guidance.
Abbott now forecasts up to 9.5% organic growth in sales, excluding COVID-19 testing, for 2024, up from the previous guidance of 8.5%.
Additionally, the company expects its adjusted EPS to range between $4.61 and $4.71, compared to the earlier forecast of $4.55 to $4.70.
Strong Q2 earnings and analyst ratings
In its recently concluded quarter, Abbott Laboratories reported a 4.0% annual growth in sales, totaling $10.38 billion, aligning with analysts’ expectations. CEO Ford described these results as “pretty impressive” during his CNBC interview.
Wall Street currently holds a consensus “overweight” rating on Abbott stock, with analysts projecting an average upside to $125, suggesting a potential 23% gain from current levels. Furthermore, Abbott offers a dividend yield of 2.17%, enhancing its attractiveness to investors.
Abbott Laboratories may see significant growth with the upcoming launch of Lingo, an innovative product that has the potential to capture a substantial market.
Despite the recent stock dip, the company’s strong financial performance, improved guidance, and promising product pipeline make it an interesting stock to keep an eye on.
The post Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product appeared first on Invezz
